Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

133.62USD
12:45pm EDT
Change (% chg)

$0.22 (+0.16%)
Prev Close
$133.40
Open
$133.55
Day's High
$135.96
Day's Low
$133.09
Volume
533,146
Avg. Vol
2,709,535
52-wk High
$145.41
52-wk Low
$96.18

Latest Key Developments (Source: Significant Developments)

European Commission grants new indication for Soliris
9:25am EDT 

Aug 21 (Reuters) - Alexion Pharmaceuticals Inc ::European Commission grants new indication for Soliris® (Eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG).EC based approval of extended indication for Soliris on comprehensive clinical data from phase 3 regain study (MG-301).EC approved extension of indication for Soliris(Eculizumab) to include treatment of refractory generalized myasthenia gravis.  Full Article

Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027
Tuesday, 15 Aug 2017 04:05pm EDT 

Aug 15 (Reuters) - Alexion Pharmaceuticals Inc :Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027.Alexion Pharmaceuticals Inc - ‍Alexion is pursuing corresponding patent applications in other regions and countries, including Europe and Japan​.  Full Article

Blueprint Medicines to evaluate advance disease discovery program opportunities
Thursday, 27 Jul 2017 06:35am EDT 

July 27 (Reuters) - Blueprint Medicines Corp :Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion.Says received written notice from Alexion of its decision to discontinue collaboration.Says believe existing cash, cash equivalents, excluding some items, to be sufficient to fund expenditure requirements into 2H 2019.  Full Article

Alexion receives positive CHMP opinion for Soliris in the EU
Friday, 23 Jun 2017 08:00am EDT 

June 23 (Reuters) - Alexion Pharmaceuticals Inc :Alexion receives positive CHMP opinion for Soliris (eculizumab) for the treatment of patients with refractory Generalized Myasthenia Gravis (GMG) in the European Union.Alexion Pharmaceuticals Inc says final decision from European Commission (EC) is anticipated in Q3 of 2017.  Full Article

Alexion Pharmaceuticals in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million
Tuesday, 13 Jun 2017 05:24pm EDT 

June 13 (Reuters) - Alexion Pharmaceuticals Inc ::Alexion Pharmaceuticals Inc - in connection with appointment as CFO, Paul Clancy will receive stock options valued about $1.2 million .Alexion-Clancy will also receive restricted stock units valued at about $5.8 million,performance share units valued at target at about $3 million.  Full Article

Alexion Pharmaceuticals names Paul Clancy as CFO
Tuesday, 13 Jun 2017 04:30pm EDT 

June 13 (Reuters) - Alexion Pharmaceuticals Inc :Alexion names Paul Clancy chief financial officer.Alexion Pharmaceuticals Inc - Clancy will succeed Dave Anderson, who will continue to serve as CFO until july 31, 2017.For past 16 years, Clancy has been employed by Biogen where he has served as CFO for last ten years.Alexion Pharmaceuticals Inc - Clancy most recently served as executive vice president, finance and CFO and a member of executive committee of Biogen.  Full Article

Alexion Pharmaceuticals says CFO will resign
Tuesday, 23 May 2017 08:00am EDT 

May 23 (Reuters) - Alexion Pharmaceuticals Inc ::Alexion Pharmaceuticals Inc says Dave Anderson, chief financial officer, will resign his position at end of August.Alexion Pharmaceuticals Inc says a search for a new CFO is underway with SpencerStuart.  Full Article

Alexion Pharmaceuticals says long-term data confirm benefits of Strensiq
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Alexion Pharmaceuticals Inc :Alexion Pharmaceuticals - long-term data confirm benefits of treatment with strensiq in adolescents and adults with hypophosphatasia through 5 years.  Full Article

Alexion Pharmaceuticals Q1 non-GAAP earnings per share $1.38
Thursday, 27 Apr 2017 06:30am EDT 

April 27 (Reuters) - Alexion Pharmaceuticals Inc ::Alexion reports first quarter 2017 results.Q1 non-GAAP earnings per share $1.38.Q1 GAAP earnings per share $0.75.Q1 revenue rose 24 percent to $870 million.Raises FY 2017 non-GAAP earnings per share view $5.10 to $5.30.Sees FY 2017 revenue $3.4 billion to $3.5 billion.Increasing GAAP EPS guidance for 2017 to $2.80 to $3.20 per share.Q1 earnings per share view $1.23, revenue view $826.6 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $5.24, revenue view $3.48 billion -- Thomson Reuters I/B/E/S.  Full Article

Alexion appoints Ludwig Hantson as chief executive officer
Monday, 27 Mar 2017 06:30am EDT 

Alexion Pharmaceuticals Inc : Alexion appoints Ludwig Hantson, Ph.D., as chief executive officer . Ludwig Hantson succeeds David R. Brennan . Hantson most recently served as president and ceo of Baxalta .Alexion Pharmaceuticals Inc - expects to appoint Brennan as chairman at annual meeting of shareholders scheduled for May 10.  Full Article

BRIEF-Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

* Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027